Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ) -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (19931)	3/21/1999 4:10:00 PM
From: Frostman	Read Replies (1) \| Respond to of 23519

<<Frosty: Although milestone payments and partnership agreements are positive actions, Rx specification, sales and earnings are the true drivers of future stock prices and higher EPS.>> Couldn't agree more. Additionally, events like milestone payments trigger interest and develop speculation regarding the potential of a company. I remember buying Vivus at $50 prior to the split, and prior to the FDA approval, plant approval, and before a single Muse package hit any shelf. The price at that time was driven by the interest in male ED products. When Vivus is tagged as a recognized player in the female SD arena, I look for a similar level of interest which may translate into share increase, again,...before FDA approval, marketing, or sales has even started. The continued growth by the company in the interim may be positive as you have suggested. I can wait. Also, I appreciate your recent contributions. You're beginning to sound like someone who might be looking for an entry point. Frostman